PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Category:
Sort By:
May 24, 2017
May 24, 2017
About ProtoKinetix, Incorporated ProtoKinetix, Incorporated (OTC: PKTX) (the  “Company” or “ProtoKinetix”) (www.protokinetix.com) today announces that it has completed the first year of retinal replacement therapy trials on animals and the...Read more
Feb 07, 2017
St. Marys, West Virginia ProtoKinetix, Incorporated (OTC: PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) updates its stockholders on the testing of neuronal retinal cells in living tissue at the University of...Read more
Jul 14, 2016
St. Marys, West Virginia ProtoKinetix, Incorporated (OTCQB:PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) is pleased to provide the following corporate update to its stockholders:The management team has been very busy since...Read more
Jun 07, 2016
St. Marys, West Virginia ProtoKinetix, Incorporated (OTCQB:PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) is pleased to announce that a paper submitted by Dr. Kevin Gregory-Evans on ProtoKinetix’ AAGP® has been published...Read more
May 02, 2016
St. Marys, West Virginia ProtoKinetix, Incorporated (OTCQB:PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) is pleased to announce that a paper submitted by Dr. Kevin Gregory-Evans on ProtoKinetix’ AAGP® has been accepted...Read more
Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.

Picture of a molecule
Picture of a molecule